4 products found
Pharmaxis Ltd Products
-
Amine Oxidase Platform
There is significant interest among leading clinicians and pharmaceutical companies in inflammatory and fibrotic diseases. Pharmaxis’ amine oxidase platform enables the synthesis of inhibitors with different pharmacological and pharmacokinetic profiles to potentially treat a number of inflammatory and fibrotic diseases.
-
Pharmaxis - Model PXS-5505 - Oral pan-LOX Inhibitor
Pharmaxis has developed an oral drug inhibiting all lysyl oxidase family members. The compound has shown significant reductions in fibrosis in in-vivo models of kidney fibrosis, lung fibrosis, myelofibrosis and pancreatic cancer. This all-encompassing LOX inhibitor is well positioned for the treatment of severe fibrosis as well as cancer with prominent stroma (connective tissue) or fibrotic metastatic niches. Pharmaxis plans to ...
-
Pharmaxis - Model PXS-6302 - Topical pan-LOX Inhibitor
Pharmaxis is developing a topical drug inhibiting all lysyl oxidase family members with potential anti-fibrotic application in severe fibrotic related scarring indications. Skin scarring after events such as accidents, surgery or burns place a substantial physical and psychological burden on ...
-
Pharmaxis - Model PXS-5382 - LOXL2 Inhibitors for Multiple Indications
The LOXL2 enzyme is fundamental to the fibrotic cascade that follows chronic inflammation in kidney fibrosis, the liver disease NASH, cardiac fibrosis and idiopathic pulmonary fibrosis (IPF), and it also plays a role in some ...
-
Pharmaxis - Model PXS-4728 - SSAO Inhibitor
Novel SSAO/VAP-1 inhibitor PXS-4728 (formerly known as BI 1467335) - for the treatment of inflammation. PXS-4728 is a very potent and highly selective compound. It is a first-in-class, mechanism-based inhibitor of Semicarbazide-Sensitive Amine Oxidase (SSAO), also known as Vascular Adhesion Protein-1 (VAP-1), or Amine Oxidase Copper Containing 3 (AOC3), PXS-4728 and provides greater than 90% inhibition of its target enzyme for 24 hours after a single oral ...